Unlike monoclonal antibodies against only IFN-a, anifrolumab targets the receptor, thereby providing a total inhibition of all type I IFNs (that is, IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω).9 Three randomised controlled trials have tested its efficacy and safety in SLE. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.